Company Profile

Cipla is currently trading at Rs. 669.10, up by 3.60 points or 0.54% from its previous closing of Rs. 665.50 on the BSE.

The scrip opened at Rs. 678.80 and has touched a high and low of Rs. 678.80 and Rs. 667.70 respectively.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 696.20 on 17-Jul-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 691.40 and Rs. 658.00 respectively. The current market cap of the company is Rs. 53659.80 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 39.92% and 23.40% respectively.

Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use.

As part of its efforts to enable speedy access to cater to the demand, the company will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet. To ensure fair and equitable distribution of the drug, supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of COVID-19 cases.

The drug has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT). As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective synthetic process for Favipiravir. The entire process and Active Pharmaceutical Ingredient (API) of the drug has been transferred to Cipla to manufacture and market the drug at scale.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use. As part of its efforts to enable speedy access to cater to the demand, the company will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet.

Precision Camshafts’ Wholly Owned Subsidiary -- PCL (International) Holding B.V. (Netherlands) has acquired balance 24% shareholding in MFT Motoren und Fahrzeugtechnik GmbH, Germany in addition to the existing 76% shareholding making it a Wholly Owned Step-down Subsidiary of the company for a total consideration of Euro 0.55 million (Rs 4.76 crore).

Jenburkt Pharmaceuticals has launched antiviral drug Favipiravir (brand name Favivent) for the treatment of mild to moderate COVID-19 symptoms at a price of Rs 39 per tablet. This is not the first foray into timely, rapid innovation from the Jenburkt stable. This innovation-driven organisation was the first in the world to introduce Nervijen, Metmin-A, Powergesic, Infartin and a few more, across multiple therapeutic areas. The company’s R&D unit, approved by the Ministry of Science & Technology, Government of India, is their gateway to health through innovation.

Hindustan Copper (HCL) is planning to enhance its ore production capacity from the current level of 4 million tonnes per annum (MTPA) to 12.2 MTPA in the first phase, and subsequently to 20.2 MTPA, in line with the government's 'Aatmanirbhar Bharat' initiative. To achieve this target, the company is looking for a suitable partner with strong financial background to expedite its future mine expansion project at a faster pace.

Prabhat Technologies (India) has received Letter of Intent with respect to the Unified License ISP Category 'A' from Department Of Telecommunications (DoT), Government of India. This Letter of Intent will facilitate in the process of obtaining the Unified License ISP Category ‘A’ for National Area Service Area, on non - exclusive basis subject to the Guidelines of Unified License.

Reliance Industries’ (RIL) telecom arm Reliance Jio Infocomm (Jio) has added 15,75,333 customers in April 2020. Following this, the company’s total customer base has increased to 38.90 crore with market share of 33.85% in terms of wireless subscribers as on April 30, 2020.

Nagarjuna Fertilizers and Chemicals has executed amendment to the escrow agreement with the lenders and gas supplier and has restarted production of urea from Plant-1 of Kakinada Plant, Andhra Pradesh on July 25, 2020.

JSW Steel’s Board has approved the raising of Long Term Funds subject to applicable regulatory approvals and market conditions, through issuance of Secured/Un-secured, Redeemable, Non-Convertible Debentures (NCDs) not exceeding Rs 10,000 crore, by way of private placement and/or by way of public issuance, in one or more tranches, in the domestic market, to be used, inter alia, to replace short maturity loans, meet long term working capital requirements, capital expenditure / reimbursement of capex already incurred and/ or for general corporate purposes. 

Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use.

As part of its efforts to enable speedy access to cater to the demand, the company will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet. To ensure fair and equitable distribution of the drug, supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of COVID-19 cases.

The drug has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT). As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective synthetic process for Favipiravir. The entire process and Active Pharmaceutical Ingredient (API) of the drug has been transferred to Cipla to manufacture and market the drug at scale.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.